Jasper Therapeutics Q2 FY26 net loss narrows to $2.76 million; R&D expense drops to $5.14 million - JSPR News | RalliesJasper Therapeutics Q2 FY26 net loss narrows to $2.76 million; R&D expense drops to $5.14 million
J
JSPR• Acquisition and financing extend runway
- The Kira Pharmaceuticals acquisition closed in July.
- A concurrent PIPE raised about USD 132 million, funding operations into the second half of 2028.
Q2 results show narrower loss and lower expenses
- Jasper Therapeutics posted a Q2 net loss of USD 2.76 million, narrowing from a USD 26.72 million loss a year earlier.
- Loss per share improved to USD 0.10 from USD 1.74 in the prior-year quarter.
- R&D expense fell to USD 5.14 million from USD 21.2 million; G&A declined to USD 4.07 million from USD 5.88 million.
- Cash and cash equivalents totaled USD 7.31 million as of June 30.
